Synapse - Martin Tallman

Search Within

Martin Stuart Tallman

Results (651)

In Philadelphia-chromosome-negative acute lymphoblastic leukemia, late relapses are not uncommon, occur mostly in patients at standard risk and have a relatively favorable outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993

Meeting Abstract

Ganzel, C.; Victoria, W. X.; Fielding, A. K.; Rowe, J. M.; Richards, S. M.; Buck, G.; Chopra, R.; Durrant, I. J.; Marks, D.; Franklin, I. M.; more...
Blood (2015)

Fulltext@MSK | Save

Hairy cell leukemia variant has similar survival to classical disease despite poorer responses to initial therapy: A 30-year experience from Memorial Sloan Kettering Cancer Center

Meeting Abstract

Getta, B.; Woo, K. M.; Devlin, S.; Park, J. H.; Abdel-Wahab, O.; Tallman, M. S.
Blood (2015)

Fulltext@MSK | Save

Very poor long-term survival, also in contemporary studies, of patients with AML who relapse after achieving a first complete remission: The ECOG-ACRIN Cancer Research Group experience

Meeting Abstract

Ganzel, C.; Cripe, L. D.; Sun, Z. X.; Fernandez, H. F.; Cassileth, P. A.; Douer, D.; Rowe, J. M.; Paietta, E.; O'Connell, M.; Wiernik, P. H.; more...
Blood (2015)

Fulltext@MSK | Save

North American leukemia, intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age >= 60 years): A trial of the ECOG-ACRIN Cancer Research Group (E2906)

Meeting Abstract

Foran, J. M.; Sun, Z. X.; Claxton, D. F.; Lazarus, H. M.; Thomas, M. L.; Melnick, A.; Levine, R. L.; Paietta, E.; Arber, D.; Zhang, Y. M.; more...
Blood (2015)

Fulltext@MSK | Save

Molecular profiling and relationship with clinical response in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class potent inhibitor of mutant IDH1, in addition to data from the completed dose escalation portion of the phase 1 study